Dupixent Approved for Chronic Spontaneous Urticaria: A New Hope for Itch Relief
For individuals battling chronic spontaneous urticaria (CSU), a condition marked by persistent hives and intense itching, a new treatment option is now available. The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for adults and adolescents aged 12 years and older with CSU who continue to experience symptoms despite antihistamine treatment. This approval, announced in April 2025, marks the first new targeted therapy for CSU in over a decade.
Understanding Chronic Spontaneous Urticaria
CSU is a frustrating and often debilitating condition where hives and itch appear without a clear trigger. Unlike allergic reactions, CSU is not caused by exposure to an allergen. The exact cause of CSU is often unknown, but it involves the immune system and inflammation within the body. It’s estimated that over 300,000 adults and adolescents in the U.S. Live with CSU that persists despite treatment with antihistamines 1.
How Dupixent Works
Dupixent is a monoclonal antibody that targets a key pathway driving inflammation in CSU. Specifically, it blocks the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two proteins that play a role in the development of hives and itch 2. By interrupting this inflammatory process, Dupixent helps to reduce the severity of symptoms and improve quality of life. Unlike traditional treatments that primarily manage symptoms, Dupixent addresses an underlying cause of the condition.
Clinical Trial Results
The FDA approval of Dupixent was based on phase 3 clinical trials that demonstrated significant reductions in itch and hives compared to placebo 1. These trials showed that Dupixent works continuously between doses to help patients get ahead of their symptoms.
What This Means for Patients
The approval of Dupixent offers a new hope for individuals with CSU who have not found adequate relief with existing treatments. Kenneth Mendez, President and CEO of the Asthma and Allergy Foundation of America, emphasized that the approval “offers patients more options and the chance to control their disease” 1.
Cost and Access
Dupixent is a prescription medication, and cost can be a concern for some patients. However, programs like DUPIXENT MyWay may be available to help eligible patients with commercial health insurance pay as little as $0 per fill 2. It’s important to discuss cost and insurance coverage with your healthcare provider.
Key Takeaways
- Dupixent is the first new targeted treatment for CSU in over ten years.
- It works by blocking IL-4 and IL-13, key drivers of inflammation in CSU.
- Clinical trials have shown significant reductions in itch and hives with Dupixent.
- Financial assistance programs may be available to help with the cost of treatment.
If you are living with CSU, talk to your doctor to see if Dupixent might be a suitable treatment option for you.
- Sanofi. Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria. April 18, 2025.
- DUPIXENT. For Chronic Spontaneous Urticaria. Accessed February 21, 2026.